Pages that link to "Q35198092"
Jump to navigation
Jump to search
The following pages link to 7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate (Q35198092):
Displaying 50 items.
- Acute Hepatotoxicity after High-Dose Methotrexate Administration to Rats (Q28325373) (← links)
- Severe renal toxicity due to intermediate-dose methotrexate (Q28342762) (← links)
- Low-dose oral pulse methotrexate as monotherapy in elderly patients with bullous pemphigoid (Q28375638) (← links)
- Molecular cloning of the cDNA coding for mouse aldehyde oxidase: tissue distribution and regulation in vivo by testosterone (Q31813048) (← links)
- A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid. (Q33497955) (← links)
- The distribution and elimination of methotrexate in mouse blood and brain after concurrent administration of polysorbate 80. (Q34051312) (← links)
- Clinical pharmacokinetics of commonly used anticancer drugs. (Q34707699) (← links)
- High dose methotrexate chemotherapy: pharmacokinetics, folate and toxicity in osteosarcoma patients (Q35640471) (← links)
- Delaying surgery with chemotherapy for osteosarcoma of the extremities (Q35784014) (← links)
- Biochemical and pharmacological consequences of the interaction between methotrexate and ketoprofen in the rabbit (Q35982202) (← links)
- Interspecies differences in the metabolism of methotrexate: An insight into the active site differences between human and rabbit aldehyde oxidase (Q36072102) (← links)
- High-dose methotrexate-associated acute renal failure may be an avoidable complication (Q36330820) (← links)
- Clinical utility and pharmacology of high-dose methotrexate in the treatment of primary CNS lymphoma (Q36492327) (← links)
- Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. (Q36694435) (← links)
- Purification, cDNA cloning, and tissue distribution of bovine liver aldehyde oxidase (Q36788353) (← links)
- Drug disposition and effect in sub-human primates used in pharmacology (Q36822423) (← links)
- Isolation and characterization of the human aldehyde oxidase gene: conservation of intron/exon boundaries with the xanthine oxidoreductase gene indicates a common origin (Q36896845) (← links)
- Mechanisms of antifolate resistance and methotrexate efficacy in leukemia cells (Q37093674) (← links)
- Preventing and Managing Toxicities of High-Dose Methotrexate (Q37496637) (← links)
- Glucarpidase following high-dose methotrexate: update on development (Q37635158) (← links)
- Methotrexate and leucovorin in malignant blood diseases (Q37732500) (← links)
- Challenges in implementing individualized medicine illustrated by antimetabolite therapy of childhood acute lymphoblastic leukemia (Q37929894) (← links)
- Pharmacokinetics and metabolism of methotrexate: an example for the use of clinical pharmacology in pediatric oncology (Q37951561) (← links)
- Practical issues with high dose methotrexate therapy (Q38243780) (← links)
- Outcomes Associated with Reducing the Urine Alkalinization Threshold in Patients Receiving High-Dose Methotrexate (Q38844526) (← links)
- Antineoplastic drugs: clinical pharmacology and therapeutic use. (Q39496661) (← links)
- Clinical pharmacokinetics of drugs used in the treatment of breast cancer (Q39533747) (← links)
- New developments on the mechanisms of action of antineoplastic drugs (Q39565319) (← links)
- Comparative distribution and embryotoxicity of methotrexate in pregnant rats and rhesus monkeys (Q39667822) (← links)
- Molybdenum hydroxylases: biological distribution and substrate-inhibitor specificity (Q39704403) (← links)
- Clinical Pharmacokinetics of Methotrexate1 (Q39720628) (← links)
- Chemoimmunotherapy of head and neck cancer (Q39722559) (← links)
- Methotrexate Disposition in Humans: Case Studies in Ovarian Cancer and Following High-Dose Infusion (Q39780182) (← links)
- Drug Treatment of Breast Cancer (Q39780277) (← links)
- High-dose Methotrexate Therapy-An Area of Uncertainty* (Q39852771) (← links)
- Pharmacokinetics of high-dose methotrexate in infants aged less than 12 months treated for aggressive brain tumors. (Q39911676) (← links)
- The renal toxicity of cancer chemotherapeutic agents (Q40102843) (← links)
- Effect of human renal and hepatic disease on the pharmacokinetics of anticancer drugs (Q40104510) (← links)
- The clinical pharmacology of methotrexate (Q40149030) (← links)
- Dose-Dependent Metabolism, Therapeutic Effect, and Toxicity of Anticancer Drugs in Man (Q40177601) (← links)
- Clinical pharmacokinetics of methotrexate in children (Q40184290) (← links)
- Dose-dependent pharmacokinetics and cancer chemotherapy (Q40313416) (← links)
- Characterization of methotrexate recovered from the urine of high dose patients for the purpose of clinical re-use (Q40561853) (← links)
- Use of Plasma Pharmacokinetics to Predict and Prevent Methotrexate Toxicity (Q40655039) (← links)
- Degradation and clearance of methotrexate in children with osteosarcoma receiving high-dose infusion (Q40686280) (← links)
- Pharmacokinetics of Methotrexate During Regional Hyperthermia in a Pig Model (Q41290508) (← links)
- Determination of Methotrexate, 7-Hydroxymethotrexate, and 2,4-Diamino-N10-methylpteroic Acid by LC-MS/MS in Plasma and Cerebrospinal Fluid and Application in a Pharmacokinetic Analysis of High-Dose Methotrexate (Q41444080) (← links)
- Methotrexate pharmacology and resistance in childhood acute lymphoblastic leukemia (Q41489289) (← links)
- The effects of diltiazem on methotrexate-induced nephrotoxicity (Q42196668) (← links)
- Proteinuria due to suboptimal hydration with high-dose methotrexate therapy (Q42287038) (← links)